Introduction
============

Lung cancer is the leading cause of cancer-related deaths worldwide. Non-small cell lung cancer (NSCLC) accounts for around 85% of all lung cancers, and majority of patients with NSCLC present with locally advanced or metastatic disease.[@b1-ott-11-3335]--[@b3-ott-11-3335] The discovery of epidermal growth factor receptor (*EGFR*) mutations in NSCLC led to a new treatment paradigm. Prospective clinical trials of first- or second-generation (1st and 2nd) EGFR-tyrosine kinase inhibitors (TKIs) demonstrated remarkable response rates of approximately 70%.[@b4-ott-11-3335]--[@b10-ott-11-3335] However, lung cancer cells inevitably acquire resistance to these inhibitors after approximately 1 year.[@b4-ott-11-3335],[@b8-ott-11-3335],[@b11-ott-11-3335] The major mechanism of acquired resistance is the *EGFR* T790M gatekeeper mutation, which accounts for approximately half of all acquired resistance to 1st- and 2nd-generation EGFR-TKIs.[@b12-ott-11-3335]--[@b14-ott-11-3335] Recently, third-generation EGFR-TKIs such as osimertinib have been shown to exert remarkable effects against *EGFR* T790M mutation-positive NSCLC. Third-generation EGFR-TKIs can bind irreversibly to the EGFR kinase by targeting the cysteine-797 residue in the ATP binding site via covalent bond formation.[@b15-ott-11-3335] Therefore, identifying T790M mutation is very important for appropriate treatment.[@b16-ott-11-3335]--[@b18-ott-11-3335] Re-biopsy could provide further information regarding the genetic profile of tumors and may help in identifying patients eligible for treatment.[@b19-ott-11-3335] Tissue biopsy is the golden standard method for re-biopsy, but several factors limit its success rate such as the difficulty of accessing tumor sites and the invasive nature of the sampling methods.[@b20-ott-11-3335]--[@b25-ott-11-3335] Given these limitations, the use of circulating tumor DNA (ctDNA), commonly named "liquid biopsy", has emerged as a new promising and less invasive tool to detect *EGFR* mutations in patients with NSCLC and can provide similar molecular information as those obtained by invasive tumor biopsies.[@b26-ott-11-3335]

In June 2016, the US Food and Drug Administration approved COBAS ver2 using plasma specimens as a companion diagnostic test for the detection of exon 19 deletions or exon 21 substitution mutations in the *EGFR* gene, and liquid biopsy for the detection of T790M has been acknowledged as one of the re-biopsy methods in Japan since December 2016. Conversely, peptide nucleic acid-locked nucleic acid polymerase chain reaction (PNA-LNA PCR) clamp method is a laboratory-developed test to detect *EGFR* mutations, including T790M. Although its sensitivity is relatively high, no study has clarified which method, PNA-LNA PCR method or COBAS ver2 method, has a higher detection rate of T790M mutation in tissue and blood.

Although the usefulness of liquid biopsy for detecting *EGFR* mutations has been recognized, the true biological meaning and equivalence of the detection methods are still under investigation. Especially, the usefulness of serum samples to detect T790M mutation has not yet been clarified.

In this study, we prospectively evaluated the sensitivity, specificity, and parallelism of the detection of *EGFR* mutations in liquid biopsy (plasma and serum samples) and tumor re-biopsy in patients with EGFR-TKI-resistant NSCLC using COBAS ver2 and PNA-LNA PCR clamp method. We aimed to identify clinical characteristics that predict the high T790M-positive rate in liquid biopsy. We also evaluated the usefulness and significance of serum testing in liquid biopsy to detect T790M mutation.

Patients and methods
====================

Patients
--------

From June 2016 to May 2017, we enrolled patients with advanced or recurrent *EGFR*-mutant NSCLC who underwent re-biopsy (2nd biopsy) based on physician's decision in the cases of acquired resistance to 1st- or 2nd-generation EGFR-TKI treatment. All tissue samples were obtained from sites assessed as disease progression by imaging. All patients were enrolled in the Keio University Hospital. Acquired resistance was defined according to Jackman's criteria.[@b27-ott-11-3335] Written informed consent was obtained from all patients. We also obtained consent from patients regarding the publication of images. This study was approved by the Ethical Review Board Committee of Keio University. Research was conducted in accordance with the 1964 Declaration of Helsinki, as revised in 2013.

Tissue re-biopsy and liquid biopsy
----------------------------------

We prospectively evaluated the sensitivity, specificity, and parallelism of the detection of *EGFR* mutations in tissue re-biopsy and liquid biopsy (plasma and serum) simultaneously. *EGFR* mutations in tumor re-biopsy were evaluated with COBAS ver2 and PNA-LNA PCR clamp method and those in liquid biopsy were evaluated with COBAS ver2 using plasma and serum. *EGFR* mutation detection in liquid biopsy was carried out by BML Inc. (Tokyo, Japan).

The amount of blood needed for plasma analysis was approximately 12 mL with EDTA as an anticoagulant. Plasma was separated from the blood cells at 4°C via low-speed centrifugation (1,200× *g* for 15 min) within 4 hours after blood draw. The pre-analytical (sample collection and processing) protocols for serum samples are simpler than those for plasma. Approximately 9 mL of blood was harvested in a normal test tube and the serum was separated from blood cells at room temperature using the same centrifugation method. These liquid samples were stored at −80°C until DNA extraction.

Clinical characteristics
------------------------

The following clinical characteristics were included in our analyses: age, sex, smoking status, the presence or absence of bevacizumab before 2nd biopsy, treatment duration with EGFR-TKIs (gefitinib, erlotinib, and afatinib), interval between diagnosis and 2nd biopsy, and the number of metastases before re-biopsy. To determine the number of metastatic sites, we counted "only one rib metastasis" as "one bone metastasis" and "one rib, one iliac, and one skull metastasis" as "three bone metastases."

Efficacy of osimertinib
-----------------------

Responsiveness to osimertinib was evaluated according to the Response Evaluation Criteria in Solid Tumors (version 1.1).[@b28-ott-11-3335]

Statistical analysis
--------------------

All categorical variables were analyzed by Fisher's exact test or Student's *t*-test, as appropriate. All *p*-values \<0.05 were considered statistically significant. Statistical analyses were conducted by using JMP software (version 13; SAS Institute, Cary, NC, USA). Data were visualized by using Easy R (Jichi Medical University, Saitama, Japan), which is a graphical user interface for R (The R Foundation for Statistical Computing, Vienna, Austria).[@b29-ott-11-3335]

Results
=======

Patient characteristics
-----------------------

Fifteen patients with NSCLC harboring *EGFR* mutations were enrolled in this study. They underwent re-biopsy after acquiring resistance to EGFR-TKIs. Patient characteristics are shown in [Table 1](#t1-ott-11-3335){ref-type="table"}. The median age was 62 years, and majority of the original *EGFR* mutations found were exon 19 deletion (53%) and exon 21 L858R (33%).

Fourteen patients were treated with erlotinib, four patients with gefitinib, and four patients with afatinib. Seven patients were treated with double EGFR-TKIs. Eleven patients were treated with erlotinib as the initial EGFR-TKI. Nine patients were treated with bevacizumab sometime before re-biopsy.

Ten patients presented positive results for *EGFR* mutations (exon 19 deletion, L858R, or T790M) in the liquid biopsy (plasma or serum) ([Figure 1](#f1-ott-11-3335){ref-type="fig"}). Of these patients, only five had a positive result for T790M with the liquid biopsy. Eight patients had a positive result for T790M with tissue re-biopsy.

Differences in the methodology between the first tumor tissue biopsy and re-biopsy
----------------------------------------------------------------------------------

There were differences in the methods used between the first biopsy (ie, at the time of first diagnosis) and re-biopsy ([Table S1](#SD1-ott-11-3335){ref-type="supplementary-material"}). CT-guided needle biopsy was used more frequently in re-biopsy than for the first biopsy.

Assay characteristics
---------------------

In 10 patients whose *EGFR* mutation was detected in liquid biopsy, the original *EGFR* mutation (exon 19 deletion or L858R) was detected in all patients: both with plasma and serum. COBAS ver2 and PNA-LNA PCR clamp method exhibited 100% sensitivity, specificity, and positive predictive value for the detection of *EGFR* exon 19 deletion (7/7) and L858R (3/3) when compared with tumor genotyping of the re-biopsy tissue. The results of *EGFR* mutation detection in tissue re-biopsy using COBAS ver2 and PNA-LNA PCR clamp method were consistent, except for one case presenting a positive result with PNA-LNA PCR clamp method, but not with COBAS ver2 ([Figure 2](#f2-ott-11-3335){ref-type="fig"}).

By contrast, the detection rate of T790M in liquid biopsy (50%) was lower than that of major *EGFR* mutation (exon 19 del or L858R, 100%) ([Table S2](#SD2-ott-11-3335){ref-type="supplementary-material"}).

The detection of T790M mutation in serum exhibited a higher specificity (67% \[4/6\]) and positive predictive value (50% \[2/4\]) than that in plasma (50% \[3/6\], 40% \[2/5\], respectively). The sensitivity for the detection of T790M was similar when using plasma and serum (50% \[2/4\]).

Clinical factors related to T790M prevalence in liquid biopsy and tissue re-biopsy
----------------------------------------------------------------------------------

When considering the results of the liquid biopsy, the number of metastases was significantly higher in the T790M-positive group than in the T790M-negative group in both plasma and serum ([Table 2](#t2-ott-11-3335){ref-type="table"}). By contrast, in tissue re-biopsy, longer duration of erlotinib treatment, but not the total duration of EGFR-TKI treatment or the number of metastases, was significantly related to T790M-positivity ([Table 3](#t3-ott-11-3335){ref-type="table"}).

Efficacy of osimertinib
-----------------------

Nine patients were treated with osimertinib. The response rate was 77.8% (7/9) and disease control rate was 100% (9/9) ([Figure 2](#f2-ott-11-3335){ref-type="fig"}). A response was observed in patients with T790M mutation detected in both tissue and liquid biopsy, only in tissue, and only in liquid biopsy. One patient was positive for T790M in liquid biopsy (both plasma and serum) and negative in tissue re-biopsy (transbronchial lung biopsy). After 2 months of gefitinib treatment, another re-biopsy of liver metastasis was performed and was positive for T790M. Afterward, the patient was treated with osimertinib and presented a response in both the lung and liver metastases ([Figure 3](#f3-ott-11-3335){ref-type="fig"}).

Discussion
==========

In the Phase III LUX-Lung 3/6 trials in patients with *EGFR* mutation-positive lung adenocarcinoma, *EGFR* mutation detection rates in ctDNA were 28.6% (serum) and 60.5% (plasma) by using RT-PCR (scorpion-ARMS) method.[@b30-ott-11-3335] Previous studies suggested that the plasma may be a more reliable source than the serum for ctDNA owing to higher background levels of non-tumor wild-type DNA found in serum. Specifically, serum yielded more cell free DNA than plasma, but the absolute quantity of mutation was higher in plasma, which may explain the differences in detection.[@b31-ott-11-3335]--[@b33-ott-11-3335] These reports suggested that the sensitivity of the detection of *EGFR* mutation in the serum is lower than that in the plasma when tumor re-biopsy is used as a reference. We prospectively performed the current study to elucidate the difference in the usefulness of plasma and serum. It is known that the detection of T790M mutation after acquired resistance is always accompanied by the original *EGFR* mutation.[@b34-ott-11-3335] We detected high concordance in terms of the sensitivity of *EGFR* mutation detection between plasma and serum samples using COBAS ver2, although the detection rate of T790M was lower than that of exon 19 deletion or L858R. Our study suggests that the detection of *EGFR* mutations in serum samples using COBAS ver2 might be as reliable as that in plasma samples.

Tissue biopsies remain the gold standard for the detection of T790M mutation, because the AURA study revealed that the efficacy of osimertinib for patients detected as T790M positive in plasma and T790M negative in the re-biopsy tissue was lower than that for patients detected as T790M positive in the tissue. Current clinical practice indicates that performing re-biopsy at the site of relapse is necessary to predict the efficacy of osimertinib because of the heterogeneous presence of T790M in the tumor tissue.[@b35-ott-11-3335] Indeed, in our study, one patient was diagnosed as presenting only an *EGFR* exon 19 deletion mutation by re-biopsy with trans-bronchial lung biopsy. However, the liquid biopsies (both plasma and serum) were positive for T790M. The patient underwent an additional re-biopsy after 2 months of targeting liver metastasis because her major relapse site was the liver. The result indicated that the patient was T790M positive. She had a remarkable response to osimertinib ([Figure 3](#f3-ott-11-3335){ref-type="fig"}).

T790M detection at the sites of relapsed tumor tissue is required to evaluate the effectiveness of osimertinib against the relapsed tumor. Using plasma samples, we may detect a little T790M clone leakage of non-relapse tumor tissue. If this is the case, we cannot predict the efficacy of osimertinib in treating relapsed tumor sites in these patients. Our data of T790M detection in liquid biopsy revealed that the specificity and positive predictive value of T790M detection in the serum were higher than those in the plasma. Thus, if the serum genotype is positive for T790M, it is likely that the patient harbored T790M mutation in the tissue, which is highly suspected to be a relapsed tumor site. These data suggest that serum samples as liquid biopsy may not detect a little T790M clone leakage from non-relapse sites. Serum samples were more reliable in the detection of T790M mutation at the relapse tumor tissue sites than plasma samples. We also suggest serum samples to be more useful than plasma samples in the detection of *EGFR* T790M mutation for determining the effectiveness of osimertinib against relapse tumor sites. If only liquid biopsy is conducted for the detection of T790M because tissue re-biopsy cannot be performed due to difficulties in accessing the tumor sites or because tumor tissue re-biopsy was negative for T790M, it might be useful to rely on the result of both serum and plasma samples. We suggest that the combined results of mutation detection using serum and plasma could provide insights into the efficacy of osimertinib treatment.

The major limitation of our study was the small sample size. Further enrollment of cases is necessary. However, we believe that the heterogeneous patient population in our study may be very important and represent population variability, resembling other studies' populations. First, the number of metastases was significantly higher in the T790M-positive group than in the T790M negative group ([Table 2](#t2-ott-11-3335){ref-type="table"}). Thress et al reported that T790M mutation was more readily detected in the plasma of patients with extra-thoracic metastatic disease than in that from patients with disease confined to the thoracic cavity (as determined by droplet digital PCR assay).[@b36-ott-11-3335] This suggests that tumor bulk and metastatic status may impact on the presence *EGFR* mutation in the plasma and should be further validated in clinical settings.[@b37-ott-11-3335] We also found that the duration of erlotinib treatment was significantly longer in the T790M-positive group than in the T790M-negative group. Several reports analyzed the relationship between T790M induction and exposure to EGFR-TKIs in preclinical and clinical studies.[@b38-ott-11-3335]--[@b40-ott-11-3335] We do not have an explanation as to why only the duration of erlotinib treatment, but not the total duration of the TKI treatment, is related to T790M positivity. One possibility may be that the total duration includes "beyond PD" treatment, ie, EGFR-TKI treatment after progression, and may not relate to the induction of T790M. Further studies are needed to confirm this possibility.

Finally, we found a case with discordant results of T790M detection in tissue re-biopsy using COBAS ver2 and PNA-LNA PCR clamp method. Previous studies reported that the detection rate of *EGFR* mutation is higher with the PNA-LNA PCR clamp method than with COBAS ver2.[@b41-ott-11-3335],[@b42-ott-11-3335] Although the companion diagnostic is COBAS ver2, one might consider using a different method like PNA-LNA PCR clamp method to confirm the T790M negative results by COBAS ver2, to detect T790M, in order to not directly rule out the possibility of osimertinib in T790M-negative cases by COBAS ver2.

Conclusion
==========

Our data suggest that plasma, serum, and tissue genotyping can have complementary roles for T790M testing by using COBAS ver2 and the PNA-LNA PCR clamp method. Especially, the result of both serum and plasma samples for T790M detection could be more useful to predict the efficacy of osimertinib than only plasma samples when tissue genotyping is negative for T790M or tissue genotyping is unknown.

Supplementary materials
=======================

###### 

Comparison between the first biopsy and re-biopsy

  Site of biopsy     First biopsy n (%)   Re-biopsy n (%)
  ------------------ -------------------- -----------------
  **Biopsy**                              
  Lung                                    
   Bronchoscopy      8 (53)               3 (20)
   CT-NB             4 (27)               8 (53)
  Lymph node                              
   Bronchoscopy      1 (7)                0
   CT-NB             0                    2 (13)
  Bone                                    
   CT-NB             1 (7)                0
  Liver                                   
   CT-NB             0                    1 (7)
  **Surgery**                             
  CNS                1 (7)                0
  **Fluid**                               
  Pleural effusion   0                    1 (7)
  **Biopsy sites**                        
  Primary            13 (87)              8 (53)
  Metastasis         2 (13)               7 (47)

**Abbreviations:** CNS, central nervous system; CT-NB, computed tomography-guided needle biopsy.

###### 

Plasma and serum assay sensitivity, specificity, and positive predictive value

  Mutation      Sensitivity, %   True positive, n   False negative, n   Specificity, %   True negative, n   False positive, n   Positive predictive value, %
  ------------- ---------------- ------------------ ------------------- ---------------- ------------------ ------------------- ------------------------------
  Exon 19 del                                                                                                                   
   Plasma       100              7                  0                   100              3                  0                   100
   Serum        100              7                  0                   100              3                  0                   100
  L858R                                                                                                                         
   Plasma       100              3                  0                   100              7                  0                   100
   Serum        100              3                  0                   100              7                  0                   100
  T790M                                                                                                                         
   Plasma       50               2                  2                   50               3                  3                   40
   Serum        50               2                  2                   67               4                  2                   50
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![Patient flow diagram.\
**Note:** L(−) denotes no mutation detected in the liquid biopsy for both original mutations and T790M.\
**Abbreviations:** T, tissue; L, liquid biopsy.](ott-11-3335Fig1){#f1-ott-11-3335}

![Waterfall plot of the percentage change in target lesion size at the initial response evaluation.\
**Notes:** The patients positive for T790M mutation in tissue re-biopsy by COBAS ver2/PNA-LNA PCR clamp method and negative in liquid biopsy (plasma/serum) are represented in black; the patients positive for T790M both in tissue re-biopsy and liquid biopsy (plasma/serum) are represented in white; the patients positive for T790M in tissue re-biopsy by PNA-LNA PCR clamp method but negative by COBAS ver2 and in liquid biopsy (plasma/serum) are represented in gray; and the patients positive for T790M in liquid biopsy (plasma/serum) and negative in tissue re-biopsy are represented by the hatched bar.\
**Abbreviations:** P, plasma; PNA-LNA PCR, peptide nucleic acid-locked nucleic acid polymerase chain reaction; S, serum; T, tissue.](ott-11-3335Fig2){#f2-ott-11-3335}

![A representative patient with osimertinib treatment.\
**Notes:** Chest x ray (**A**) prior to and (**B**) after treatment with osimertinib for 2 months. Abdomen computed tomography (**C**) prior to and (**D**) after treatment with osimertinib. This patient was T790M negative with tissue re-biopsy (lung) and T790M positive with liquid biopsy. Re-biopsy of liver metastasis (white arrows) revealed T790M positivity 2 months after the first lung re-biopsy. Osimertinib treatment resulted in tumor shrinkage both in the lung and liver.](ott-11-3335Fig3){#f3-ott-11-3335}

###### 

Patient characteristics (n=15)

  Age, year, median (range)                                     62 (44--84)
  ------------------------------------------------------------- -----------------------------------------------
  Sex, n (%)                                                    
   Male                                                         5 (33)
   Female                                                       10 (67)
  Original mutation, n (%)                                      
   Exon 19 deletion                                             8 (53)
   L858R                                                        5 (33)
   G719C                                                        1 (7)
   G719S                                                        1 (7)
  Smoking status, n (%)                                         
   Never                                                        8 (53)
   Former                                                       7 (47)
  EGFR-TKIs, n                                                  
   Erlotinib                                                    14[a](#tfn1-ott-11-3335){ref-type="table-fn"}
   Gefitinib                                                    4
   Afatinib                                                     4
  Bevacizumab as prior therapy, n (%)                           
  Yes                                                           9 (60)
  Duration of erlotinib treatment, m, median (range)            10 (0--29)
  Duration of all EGFR-TKIs treatment, m, median (range)        23 (3--59)
  Interval between diagnosis and re-biopsy, m, median (range)   35 (10--140)
  Number of metastases, n, median (range)                       3 (0--9)

**Notes:**

Seven patients were treated with double EGFR-TKIs. Eleven patients were treated with erlotinib as the initial line of EGFR-TKIs.

**Abbreviations:** EGFR-TKIs, epidermal growth factor receptor-tyrosine kinase inhibitors; m, months.

###### 

Univariate analyses of patient characteristics and T790M prevalence (plasma and serum)

  Patient characteristics                              T790M+ (plasma)   T790M− (plasma)   *p*-value   T790M+ (serum)   T790M− (serum)   *p*-value
  --------------------------------------------- ------ ----------------- ----------------- ----------- ---------------- ---------------- -----------
  Age, year                                     \>65   2                 3                 1           2                3                1
  Sex, n                                        Male   0                 2                 0.44        0                2                0.47
  Smoking status, n                             Yes    0                 3                 0.17        0                3                0.2
  Bevacizumab as prior therapy, n               Yes    4                 2                 0.53        4                2                0.077
  Duration of erlotinib treatment, m                   7.6±3.9           11±3.9            0.56        8.5±4.5          9.8±3.7          0.82
  Duration of all EGFR-TKIs treatment, m               13.8±7.7          24.1±5.6          0.38        16.3±9.0         20.1±7.4         0.71
  Interval between diagnosis and re-biopsy, m          31.2±16.2         59.0±16.2         0.26        34.5±19.1        52.2±15.6        0.49
  Number of metastases, n                              6.2±0.8           2.0±0.8           0.006       6.5±1.0          2.5±0.8          0.013

**Note:** Data are shown as mean ± SD.

**Abbreviations:** EGFR-TKIs, epidermal growth factor receptor-tyrosine kinase inhibitors; m, months.

###### 

Univariate analyses of patient characteristics and T790M prevalence in tissue biopsy

  Patient characteristics                                   T790M+ (tissue)   T790M− (tissue)   *p*-value
  --------------------------------------------- ----------- ----------------- ----------------- -----------
  Age, n                                        \>65 year   4                 3                 1
  Sex, n                                        Male        3                 2                 1
  Smoking status, n                             Yes         4                 4                 1
  Bevacizumab as prior therapy, n               Yes         6                 3                 0.31
  Duration of erlotinib treatment, m                        16±2.2            6.3±2.4           0.01
  Duration of all EGFR-TKIs treatment, m                    19.9±5.6          22.3±5.6          0.77
  Interval between diagnosis and re-biopsy, m               52.3±12.8         40.3±13.7         0.53
  Number of metastases, n                                   19.9±5.3          18.9±5.6          0.9

**Note:** Data are shown as mean ± SD.

**Abbreviations:** EGFR-TKIs, epidermal growth factor receptor-tyrosine kinase inhibitors; m, months.
